Glucose: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: May 15, 2026

Glucose

Active ingredient · 3 therapeutic classes

Sold as DIORALYTE NATURAL

GB MHRA

Drug class: Other Irrigating Solutions
Availability: See label
Markets covered: 1
Products on record: 51

B05CXOther Irrigating Solutions V04CATests For Diabetes V06DCCarbohydrates

Overview

Glucose is an active pharmaceutical ingredient in the Other Irrigating Solutions group (B05CX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	51	May 15, 2026

GBUnited Kingdom· MHRA

51 products

Uses

GBOfficial regulatory label· revised May 15, 2026[1]

Vantonex is indicated in adults and children for rapid therapy of severe depletion or malabsorption of the water soluble vitamins B and C: • particularly in alcoholism, where a severe depletion of thiamine can lead to Wernicke's encephalopathy • after acute infections • post-operatively • in psychiatric states Also used to maintain levels of vitamin B and C in patients on chronic intermittent haemodialysis.

How to take

Sources & citations

[1]MHRA (UK) · PLGB540540008 · revised May 15, 2026

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised May 15, 2026[1]

Adverse reactions reported as possibly associated to Vantonex are presented in the following table by MedDRA System Organ Class (SOC), Preferred Term and frequency.
The following frequency categories are used:
Very common (>1/10); Common (>1/100, <1/10); Uncommon (>1/1,000, <1/100); Rare (>1/10,000, <1/1,000); Very rare (<1/10,000), including isolated reports. Post-marketing adverse reactions are reported voluntarily from a population with an unknown rate of exposure.
Therefore, it is not possible to estimate the true incidence of adverse reactions and the frequency is “unknown”. Tabulated summary of adverse reactions SYSTEM ORGAN CLASS (SOC) FREQUENCY ADVERSE REACTION Immune system disorders Unknown Hypersensitivity (including anaphylaxis, rash and urticaria) Nervous system disorders Unknown Paraesthesia Vascular disorders Unknown Hypotension General disorders and administration site conditions Unknown Injection site reactions (including pain and swelling) Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised May 15, 2026[1]

Although potentially serious allergic adverse reactions such as anaphylactic shock may occur rarely during, or shortly after, parenteral administration of Vantonex, such rare occurrence of serious allergic reactions should not preclude the use of Vantonex in patients who need treatment by this route of administration particularly those at risk of Wernicke's encephalopathy - for whom treatment with parenteral thiamine is essential.
Initial warning signs of a reaction to Vantonex are sneezing or mild asthma and those treating patients need to note that the administration of further injections to such patients may give rise to anaphylactic shock. Facilities for treating anaphylactic reactions should be available whenever Vantonex is administered.
To minimise the risk of such events with Vantonex, this medicinal product should be administered by infusion over a period of 30 minutes. This medicine is for injection into a vein only and should not be given by any other route Care should be taken to ensure that the route of administration used (intramuscular or intravenous) is that intended – reports of unintentional administration by the wrong route have been received; these incidents have not been associated with serious adverse reactions.
In common with all parenteral products each ampoule should be visually inspected prior to administration and should not be used if particulates are present.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drugs in the same class

Sources & citations